Nicole Woods-Dipace
Family · Lawrenceville, NJNPI 1275256471
Payments from drug & device makers
Across 90 payments — averaging $20.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$277
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$181
- AstraZeneca$178
- Idorsia Pharmaceuticals US Inc$156
- AbbVie$151
- Novo Nordisk$143
- plus $771 from 16 others
What the payments were for
- Food & beverage$1,858100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 11 | $277 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 9 | $181 |
| AstraZeneca | 10 | $178 |
| Idorsia Pharmaceuticals US Inc | 9 | $156 |
| AbbVie | 5 | $151 |
| Novo Nordisk | 7 | $143 |
| Lilly USA, LLC | 7 | $139 |
| Pfizer | 6 | $138 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $82 |
| Merck | 4 | $72 |
| GSK | 3 | $67 |
| Astellas Pharma US Inc | 2 | $51 |
| Esperion Therapeutics, Inc. | 2 | $32 |
| Boehringer Ingelheim | 2 | $27 |
| Sunovion Pharmaceuticals Inc. | 1 | $24 |
| Novartis | 1 | $22 |
| Sanofi-aventis U.S. LLC | 1 | $22 |
| Sumitomo Pharma America, Inc. | 1 | $21 |
| Johnson & Johnson | 1 | $20 |
| Exact Sciences | 1 | $20 |
| IBSA Pharma Inc. | 1 | $18 |
| Radius Health, Inc. | 1 | $16 |
How this compares
$1,858 in reported general payments places this provider in the 85th percentile of 2,692 family providers in New Jersey.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 28 | $23,197 |
| MounjaroTirzepatide | 12 | $11,394 |
| OzempicSemaglutide | 11 | $10,218 |
| MyrbetriqMirabegron | 16 | $7,304 |
| SynthroidLevothyroxine Sodium | 11 | $979 |
| Nebivolol Hcl | 15 | $784 |
| Tamsulosin Hcl | 22 | $784 |
| Rosuvastatin Calcium | 68 | $783 |
| Pantoprazole Sodium | 23 | $564 |
| Valsartan | 15 | $452 |
| Celecoxib | 14 | $392 |
| Levothyroxine Sodium | 41 | $385 |
| Ezetimibe | 12 | $375 |
| Atorvastatin Calcium | 47 | $338 |
| Escitalopram Oxalate | 21 | $305 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $138 | $23,19728 claims |
| Lilly USA, LLCMounjaro | $139 | $11,39412 claims |
| Novo NordiskOzempic | $143 | $10,21811 claims |
| Astellas Pharma US IncMyrbetriq | $51 | $7,30416 claims |
| AbbVieSynthroid | $151 | $97911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,692 family providers in New Jersey.
Other family in Lawrenceville
- Jennifer DemaioMorristown$412K
- Kara TrlicaCranbury$186K
- Nicole BauerParamus$161K
- Angie GarciaWest New York$161K
- China BattistaWall Township$142K
- Nancy EisenbergerVoorhees$82K
- Jennifer AbitabiloGlen Ridge$54K
- Megan FiloramoMorristown$53K
- Shawn DenningToms River$29K
- Kimberly ClementeEatontown$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.